-
2024-518061-10-00
4
2023-09-13
Severe Alcohol Use Disorder
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2023-504999-25-00
5
2023-07-14
Acute Myeloid Leukemia
-
2022-502703-30-00
6
2023-06-28
neuroendocrine tumours
-
2022-501504-95-00
4
2023-06-23
Non-metastatic HER2-positive Breast Cancer
-
2022-501710-62-02
6
2023-06-07
Peripheral T-cell lymphoma (PTCL)
-
2024-518059-50-00
5
2023-03-01
Orthopedic surgery
-
2022-501181-22-01
4
2023-02-06
Pancreatic adenocarcinoma
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria
-
2022-500311-39-00
6
2022-09-08
Patients with Crohn's disease undergoing surgery and having at least o
-
2023-505360-11-00
4
2022-08-18
solid tumour
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-505512-37-00
5
2022-06-07
Acute Myeoloid Leukemia
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516623-14-00
4
2021-03-17
EBV+ primary imunodeficiency lymphoproliferative disease (LPD)
-
2023-505187-11-00
7
2021-03-01
Duchenne Muscular Dystrophy
-
2022-502737-26-00
4
2020-12-15
epidermoid carcinoma
-
2024-511454-45-00
7
2020-11-09
Relapsed or Refractory Multiple Myeloma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2024-515625-29-00
5
2020-06-16
Apnea of prematurity
-
2024-512654-19-00
5
2020-03-06
Sickle Cell Disease